Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

Loading...
Loading...

NEW YORK and BASEL, Switzerland, May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. AXGT, a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani, Pharm.D., SVP of Commercial Strategy and Operations, will present at the Jefferies Global Virtual Healthcare Conference.

Presentation Details:

Date: Thursday, June 4, 2020
Time: 3:00 PM EDT
Webcast link: http://wsw.com/webcast/jeff126/axgt/ 

A replay of the presentation will be available in the Events section of Axovant's website at www.axovant.com for approximately 30 days following the conference.

About Axovant Gene Therapies

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), and Parkinson's disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.

Forward Looking Statements and Information

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "would," "should," "expect," "believe," "estimate," and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based on estimates and assumptions by Axovant's management that, although Axovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Axovant expected. Such risks and uncertainties include, among others, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the expectations for regulatory submissions and approvals; the continued development of its gene therapy product candidates and platforms; Axovant's scientific approach and general development progress; and the availability or commercial potential of Axovant's product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Axovant's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 10, 2020, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Axovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Media and Investors Contact:

Parag Meswani
Axovant Gene Therapies
(212) 547-2523
investors@axovant.com 
media@axovant.com

Loading...
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...